skip to Main Content
 

Three Quick Facts: GlaxoSmithKline, Next and Fever-Tree

*

GlaxoSmithKline [LSE: GSK]

GlaxoSmithKline has this morning announced that regulators have approved a new vaccination which the company has developed for use in Japan and Europe. The drug helps protect those aged over 50 against contracting shingles, but whether this news will provide much in the way of direction for shares remains to be seen. Whilst nearly all adults over 50 have the shingles virus lying dormant in their nervous system, and 1.7 million Europeans reportedly suffer from the condition each year, the vaccine received the relevant approvals in the lucrative US market back in October. The good news might already be largely priced in.


Next [LSE: NXT]

It’s been a poor week for retailers so this morning’s full year results from fashion chain Next have been under close scrutiny. A sigh of relief therefore that revenues have come in as expected, down a shade on the same period a year ago. The company had in recent years been battling with the decline of customers buying goods using a credit account, which was a profitable division for the company. The relaunch of this division of the business has helped stabilise performance here and in a rising interest rate environment could prove vital for the firm going forward.

FeverTree Drinks [LSE: FEVR]

One of Fever-Tree’s founders announced that he intended to sell a cool 1.5 million shares in the company. With an order that big you don’t just call up your stockbroker, rather the shares are placed into the market by an institutional broker. Demand was however so strong that Charles Rolls ended up disposing of 3 million shares at £27.50 each. However this certainly isn’t a founder turning his back on the business – Mr Rolls still owns the best part of 10 million further shares in the company.

Like this article? Sign up to our free newsletter.

This article does not constitute investment advice. Do your own research or consult a professional advisor.

The Armchair Trader's 'How to' Guides

In-depth Reports

Detailed reviews of selected companies and investment trusts.

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

Aquis
FP Markets
IG
Pepperstone
WisdomTree
CME Group
Back To Top